Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
NIFEDIPINE
Stada Arzneimittel AG
5 Milligram
Capsule
1997-04-04
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nifedipine 5 mg STADA Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 5 mg Nifedipine For excipients, see 6.1. 3 PHARMACEUTICAL FORM Soft capsule. Brown capsule, oval, content consists of a yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS (i) Chronic stable angina. (ii) mild to moderate hypertension. 4.2 POSOLOGY AND METHOD OF ADMINSTRATION 4.2.1 DOSAGE Adults / Elderly: The recommended dose is 5 to 10 mg three times a day. The maximum daily dose should not exceed 20 mg three times a day. Patients with hepatic dysfunction should commence therapy at 5 mg three times a day. No dosage adjustment is normally required in patients with renal dysfunction. Therapy may be indefinitely continued. Children: Not recommended. 4.2.2 ADMINISTRATION For oral administration only. 4.3 CONTRAINDICATIONS Use in patients hypersensitive to the active ingredient. Use in patients with cardiogenic shock. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Issued 29/09/2005_ _CRN 2012633_ _page number: 1_ Unstable angina pectoris. Acute myocardial infarction (within the first 4 weeks). Use in women capable of child-bearing or to nursing mothers. 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE The use of nifedipine in diabetic patients may require adjustment of their control. Nifedipine should be used with caution in patients with poor cardiac reserve or severe hypotension. Deterioration of heart failure has occasionally been observed with nifedipine. The introduction of nifedipine therapy may induce attacks of ischaemic pain in some patients with angina pectoris commonly within 30 minutes of taking nifedipine. Should this occur treatment should be stopped. Patients should be Read the complete document